Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27524359 | 1.00 | NAAA (0.47) | NAAAPPARGEPHX1TSHREPHX2 | |
| SCHEMBL12584054 | 0.94 | ALDH1A1 (0.41) | NAAAPPARGTSHREPHX2HCAR2 | |
| SCHEMBL17049674 | 0.94 | ALDH1A1 (0.41) | NAAAPPARGTSHREPHX2HCAR2 | |
| SCHEMBL1297108 | 0.88 | NAAA (0.59) | NAAAPPARGEPHX1TSHREPHX2 | |
| SCHEMBL1297175 | 0.88 | NAAA (0.59) | NAAAPPARGEPHX1TSHREPHX2 | |
| SCHEMBL19348900 | 0.88 | NAAA (0.59) | NAAAPPARGEPHX1TSHREPHX2 | |
| SCHEMBL11833028 | 0.88 | NAAA (0.59) | NAAAPPARGEPHX1TSHREPHX2 | |
| SCHEMBL1296605 | 0.88 | NAAA (0.59) | NAAAPPARGEPHX1TSHREPHX2 | |
| SCHEMBL11823716 | 0.88 | NAAA (0.59) | NAAAPPARGEPHX1TSHREPHX2 | |
| SCHEMBL1296550 | 0.88 | NAAA (0.59) | NAAAPPARGEPHX1TSHREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| WO-2022084741-A1 | CFTR MODULATOR COMPOUNDS, COMPOSITIONS, AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | PDE4A, PDE4B, PDE5A | NAAA 2171/4885PPARG 647/4885EPHX1 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.